Manidipine 

Manidipine is an orally active calcium channel antagonist. Manidipine regulates the expression of cytokines (IL-1β, IL-6). Manidipine has a hypotensive effect. Manidipine can be used in the study of cardiovascular diseases (such as hypertension, myocardial ischemia-reperfusion injury, ventricular hypertrophy), kidney diseases (such as glomerular diseases), and epilepsy^{[1][2][3][4][5][6][7][8]}.

Manidipine (1 nM-1 μM; 1-4 h) inhibits the transcription of mRNA for IL-1β and GM-CSF, while enhancing the transcription of IL-6 gene in human mesangial cells stimulated by PDGF-BB^[1].
Manidipine (0.1 nM-1 μM; 20-60 min) inhibits the ET-1-induced [Ca²⁺]i increase in A7r5 cells and glomerular mesangial cells^[2].
Manidipine (1-5 μM; 18 h) completely inhibits IL-6 production induced by acLDL, oxLDL or TNF-α in human endothelial cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Manidipine (1-10 mg/kg; p.o.; once a day; 7 days) reduces systolic blood pressure, increases plasma nitrite/nitrates, and shows a dose-dependent cardioprotective effect against ischemia-reperfusion injury in normocholesterolemic rats^[6].
Manidipine (3 mg/kg; i.g.; once a day; 7 days) hydrochloride prevents Isoproterenol (HY-B0468)-induced left ventricular hypertrophy and the increase in ANP, collagen types I and III, and fibronectin mRNAs in rats^[4].
Manidipine (0.05% in rat chow; p.o.; 2 months or 20 μg/kg; i.v.) hydrochloride shows antihypertensive effect in spontaneously hypertensive rats^[5].
Manidipine (10-30 mg/kg; i.p.; before administration of agents that induced seizures) increases the latency to convulsions and the time of death in PTZ-induced seizure mice^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

610.70

C₃₅H₃₈N₄O₆

89226-50-6

Solid

Light yellow to yellow

O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCN3CCN(C(C4=CC=CC=C4)C5=CC=CC=C5)CC3

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Roth M, et al. Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci U S A. 1992 May 1;89(9):4071-5.  [Content Brief]

  [2]. Huang S, et al. Manidipine inhibits endothelin-1-induced [Ca2+]i signaling but potentiates endothelin's effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cells. Am Heart J. 1993 Feb;125(2 Pt 2):589-97.  [Content Brief]

  [3]. Costa S, et al. Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages. Pharmacol Res. 2010 Sep;62(3):265-70.  [Content Brief]

  [4]. Yoshiyama M, et al. Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricular hypertrophy. Jpn Circ J. 1998 Jan;62(1):47-52.  [Content Brief]

  [5]. Tojo A, et al. Effects of manidipine hydrochloride on the renal microcirculation in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1992 Dec;20(6):895-9.  [Content Brief]

  [6]. Rossoni G, et al. Combined simvastatin-manidipine protect against ischemia-reperfusion injury in isolated hearts from normocholesterolemic rats. Eur J Pharmacol. 2008 Jun 10;587(1-3):224-30.  [Content Brief]

  [7]. Haraguchi K, et al. Catalepsy induced by manidipine, a calcium channel blocker, in mice. J Pharm Pharmacol. 1996 Apr;48(4):429-32.  [Content Brief]

  [8]. Souza C N S, et al. 074—(SOA0068) Anticonvulsant activity of acute treatment with manidipine in pentylenetetrazole-and pilocarpine-induced seizure models in mice. Epilepsy & Behavior, 2014, 38: 214.